Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Correlates of Protection from Tuberculosis
Chapter
Alvarez MPP. et al, (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 99 - 137
Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
Journal article
Hillson K. et al, (2021), The Lancet, 398, 1683 - 1684
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Journal article
Emary KRW. et al, (2021), The Lancet, 397, 1351 - 1362
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891
Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination.
Journal article
Bitencourt J. et al, (2021), Frontiers in immunology, 12
Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination
Other
Bitencourt J. et al, (2021)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Journal article
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Journal article
Arrieta O. et al, (2020), JAMA oncology, 6, 856 - 864
Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries.
Journal article
Cardona AF. et al, (2020), Therapeutic advances in respiratory disease, 14
Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
Journal article
Fedosyuk S. et al, (2019), Vaccine, 37, 6951 - 6961
Cancer immunotherapy-associated hypophysitis.
Journal article
Castillero F. et al, (2019), Future oncology (London, England), 15, 3159 - 3169
Budget Impact Analysis of Immunotherapy as Second-line Treatment of NSCLC at MX's National Institute of Cancer
Conference paper
Ramirez Tirado LA. et al, (2019), JOURNAL OF THORACIC ONCOLOGY, 14, S1196 - S1196
Lung Immune Prognostic Index in Patients with Non-small Cell Lung Cancer Treated with Either Chemo or Immunotherapy
Conference paper
Barron F. et al, (2019), JOURNAL OF THORACIC ONCOLOGY, 14, S1195 - S1195
Normalization of Carcinoembryonic Antigen Levels Are Associated with a Survival Improvement in Advanced Non-Small Cell Lung Cancer Patients
Conference paper
Sanchez Reyes R. et al, (2019), JOURNAL OF THORACIC ONCOLOGY, 14, S1185 - S1186
Necrotising enterocolitis: Case series, of General Hospital of Mexico Dr. Eduardo Liceaga
Journal article
Sansón-Riofrío L. et al, (2018), Revista Médica del Hospital General de México, 81, 211 - 216
The use of immunotherapy for the treatment of tuberculosis.
Journal article
Ramos-Espinosa O. et al, (2018), Expert review of respiratory medicine, 12, 427 - 440